MariMed (MRMD) Expected to Release Quarterly Earnings on Wednesday

MariMed (OTCMKTS:MRMD) is projected to release its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect MariMed to announce earnings of ($0.01) per share and revenue of $39.80 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:00 AM ET.

MariMed (OTCMKTS:MRMD) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). The company had revenue of $39.48 million during the quarter, compared to analyst estimates of $38.75 million. MariMed had a negative net margin of 7.82% and a negative return on equity of 5.00%.

MariMed Stock Performance

OTCMKTS:MRMD opened at $0.07 on Monday. MariMed has a 12 month low of $0.06 and a 12 month high of $0.23. The company has a current ratio of 0.95, a quick ratio of 0.34 and a debt-to-equity ratio of 1.67. The firm’s 50 day moving average is $0.07 and its 200 day moving average is $0.08. The stock has a market capitalization of $27.20 million, a PE ratio of -2.26 and a beta of 1.33.

About MariMed

MariMed Inc is a multi‐state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult‐use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.

The company’s product portfolio includes branded flower, pre‐rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs.